UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

66.83EUR
8:03am EDT
Change (% chg)

€-0.71 (-1.05%)
Prev Close
€67.54
Open
€67.05
Day's High
€67.67
Day's Low
€65.66
Volume
77,471
Avg. Vol
289,768
52-wk High
€74.25
52-wk Low
€59.01

UCB.BR

Chart for UCB.BR

About

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.59
Market Cap(Mil.): €13,136.91
Shares Outstanding(Mil.): 194.51
Dividend: 0.80
Yield (%): 1.18

Financials

  UCB.BR Industry Sector
P/E (TTM): 59.57 35.90 36.13
EPS (TTM): 1.13 -- --
ROI: 3.14 15.37 14.83
ROE: 4.32 15.94 15.69
Search Stocks

European shares mark positive end to rebound month

* UCB, BNP Paribas, Natixis up after results (Updates with closing prices, writes through)

31 Jul 2015

European shares edge lower, commodity stocks weigh

LONDON, July 31 - European shares fell slightly after hitting a one-week high on Friday, with commodity stocks leading the market lower after prices of crude oil and major industrial metals dropped on supply-demand concerns.

31 Jul 2015

European shares edge higher, positive earnings help

LONDON, July 31 - European shares advanced for a fourth straight session to a one-week high on Friday, with forecast-beating earnings reports from some companies underpinning market sentiment.

31 Jul 2015

European shares steady, UCB and Airbus gain after results

LONDON, July 31 - European shares steadied in early trading on Friday after having risen in the previous three sessions, with some companies posting strong gains after announcing forecast-beating results.

31 Jul 2015

European Factors to Watch-Shares seen up for 4th day, focus on earnings

LONDON, July 31 - European shares were expected to advance for a fourth straight session on Friday, with some forecast-beatings company results seen as underpinning positive market sentiment.

31 Jul 2015

BRIEF-UCB H1 net profit jumps to 289 million euros

* Reports H1 net profit increased to 289 million euros ($316.34 million) from 113 million euros a year ago

31 Jul 2015

UCB raises 2015 forecast as core drugs outperform

BRUSSELS, July 31 - Belgian pharmaceutical company UCB raised its 2015 forecasts on Friday as sales of its three major upcoming drugs propelled first-half earnings by more than expected.

31 Jul 2015

BRIEF-UCB announces Epratuzumab in Systemic Lupus Erythematosus phase III trial did not meet primary endpoint

* UCB announces Phase 3 clinical trial program for Epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

28 Jul 2015

BRIEF-UCB announces data from Neupro phase 3 study

* Announces first presentation of data from Neupro (rotigotine transdermal patch) phase 3 study in China at international congress

16 Jun 2015

BRIEF-UCB to license Oncodesign program targeting neurological diseases

* Says UCB SA exercises its option to license a program from Oncodesign targeting neurological diseases

05 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : ValuEngine, Inc.
$49.00
Provider : Sadif Analytics Prime
$25.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks